KZA 0.00% 8.0¢ kazia therapeutics limited

Given that the upcoming DIPG combination trial will use 2 drugs,...

  1. 856 Posts.
    lightbulb Created with Sketch. 356
    Given that the upcoming DIPG combination trial will use 2 drugs, one which blocks the glucose utilization pathway (paxalisib) and one which blocks the oxidative pathway (IIRC), I think it would be worth it to try paxalisib in combination with Cantrixil to see what happens, as Cantrixil also seems to affect the oxidative pathway (thereby blocking the 2 major pathways for excessive metabolism in cancer cells).
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.